Does 17 Alpha-Hydroxyprogesterone Caproate Decrease the Rate of
Preterm Birth in Women with an Ultrasound-Indicated Cerclage?
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ABSTRACT

RESULTS

Objective To estimate whether the use of 17 alpha-hydroxyprogesterone caproate (17P) in women

• 59 women with a prior PTB and current UIC were identified:

Figure 1: PTB outcomes (17P vs No 17P)
70

with an ultrasound-indicated cerclage (UIC) reduces the rate of preterm birth (PTB).

Methods Retrospective cohort study of women with a 1) previous spontaneous PTB between 20-36

Results 59 women with a prior PTB and current UIC were identified. 15 women (25.4%) received 17P,

17P: 15 (25.4%)

Table 1: Demographics
17P

No 17P

n=15 (%)

n=44 (%)

28 [25-33]

28 [25-33]

14 (93.3)
1 (6.7)

32 (72.7)
12 (27.3)

0.15

Smoking

3 (20.0)

11 (25.0)

0.99

>1 Dilation and Curettage

3 (20.0)

11 (25.0)

0.99

History of Cone Biopsy

3 (20.0)

2 (4.5)

0.10

History of >1 PTB

6 (40.0)

16 (36.4)

0.80

Earliest GA (wk) of Prior PTB*

25 [20-32]

22 [20-24]

0.06

GA (wk) at Cerclage Placement*

21 [16-22]

19 [17-21]

0.38

Pre-Cerclage Shortest CL (mm)*

18 [12-22]

17 [12-20]

0.64

Variable

Conclusion Among women with a prior spontaneous PTB and current UIC for CL<25mm, 17P did not
reduce the rate of PTB <35 weeks.

• Placing an ultrasound-indicated cerclage (UIC) once the transvaginal
cervical length (TV CL) falls below 25mm between 16-23 6/7 weeks’
gestation in women with a previous preterm birth (PTB) has been shown to
reduce the rate of PTB.
• In women with a prior PTB, weekly 17 alpha-hydroxyprogesterone caproate
(17P) has also been shown to be beneficial in reducing the rate of PTB.
• While the most recent randomized study on UIC involved many women
receiving 17P, the earlier studies did not have women on 17P, as at that
time, it was not yet standard of care.
• Our objective was to examine the efficacy of 17P at prolonging
gestation in women with a prior PTB, who have received an UIC.

MATERIALS & METHODS

No 17P: 44 (74.6%)

• Baseline characteristics (Table 1) did not differ between the two groups.

while 44 (74.6%) did not. Baseline characteristics (age, race, smoking history, >1 dilation and curettage,
history of cone biopsy, number of prior PTBs, earliest GA of prior PTB, GA at cerclage placement,
shortest CL prior to cerclage) did not differ between the two groups. 17P was not associated with
significant effects on the primary or secondary outcomes.

BACKGROUND

Age*
Race

African American
Caucasian

0.85

40
30
20
10
0

<37 Weeks

<35 Weeks

<32 Weeks

OR 2.89 (0.84, 9.89)

OR 1.59 (0.47, 5.38)

OR 1.70 (0.47, 6.14)

Figure 2: Kaplan-Meier (17P vs No 17P)
17P
No 17P

• 17P was not associated with significant effects on the primary or
secondary outcomes (Table 2, Figures 1 and 2).

Table 2: Delivery Outcomes*

• Inclusion criteria: singleton gestation, previous spontaneous PTB between
20-36 6/7 weeks, asymptomatic women with TV CL <25mm, with or without
usage of 17P, UIC placed between 15-23 6/7 weeks.

Median gestational age at delivery (p value 0.17)

• The primary outcome variable was PTB <35 weeks. Secondary
outcomes included PTB <32 weeks, PTB <37 weeks, GA at delivery,
and neonatal birthweight.

p

50

*Data presented as Median [IQR]

• This was a retrospective cohort study, using data from an existing prematurity
database (1995-2009).

• Exclusion criteria: multiple gestations, history or physical-exam indicated
cerclage, indicated PTB, major fetal anomalies.

No 17P

60

% Delivered

weeks and 2) current UIC placement for cervical length (CL) <25mm between 15-23 6/7 weeks. The
study group consisted of women treated with 17P starting at 16-20 weeks, and the control group
consisted of women who were not treated with 17P. Primary outcome was PTB <35 weeks. Secondary
outcomes included PTB <32 weeks, PTB <37 weeks, gestational age (GA) at delivery, and birthweight.

17 P

17P
35 weeks (27-38 wks)
No 17P 38 weeks (33-39 wks)
Median neonatal birthweight (p value 0.50)

17P
2381g (1724-3196g)
No 17P 2920g (1800-3380g)
*Data presented as Median (IQR)

CONCLUSIONS
• Among women with a prior spontaneous PTB and current UIC
for CL<25mm, 17P did not reduce the rate of PTB <35 weeks.
• 17P did not seem to have a prolonging effect on gestation, nor did it have
an effect on neonatal birthweight.
• There was a non-significant trend toward increased odds of PTB and lower
birthweights in the 17P group compared with the No 17P group.

